EORTC 26981/22981 – Concomitant and adjuvant Temozolomide and Radiotherapy for newly diagnosed glioblastoma multiforme.
A randomized phase III study.
A landmark EORTC study that found that the combination of the chemotherapy drug temozolomide (TMZ) and radiotherapy, improved survival rates without sacrificing health-related quality of life (HRQOL) scores, in patients with glioblastoma (GBM). This combination treatment became the standard of care for newly diagnosed glioblastoma patients worldwide. This study also identified the MGMT gene promoter methylation as the first predictive marker in brain tumors and introduced the concept of personalized treatment into neuro-oncology.